Narikazu Boku

20PUBLICATIONS
98CO-AUTHORS
Cancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Mar 15, 2026
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Takeru Wakatsuki, Noriko Yamamoto, Naoki Ishizuka

|Mar 12, 2026
Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study.

Narikazu Boku

|Feb 02, 2026
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Chie Kudo-Saito, Hirokazu Shoji, Kengo Nagashima

|Jan 08, 2026
Genomic Profile and Resistance to Anti-Epidermal Growth Factor Receptor Antibody in RAS-Amplified Colorectal Cancer: A Study Based on a Japanese Cancer Genome Database.

Gota Fujisawa, Kenji Tamada, Takeshi Hayashi

|May 23, 2025
Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.

Daisuke Sakai, Shigenori Kadowaki, Ryohei Kawabata

|May 16, 2025
Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Hisato Kawakami, Shigenori Kadowaki, Akitaka Makiyama

Pageof 4

Frequent Collaborators

3 joint publications

Takeru Wakatsuki

3 joint publications

Hisato Kawakami

3 joint publications

Hirokazu Shoji

3 joint publications

Daisuke Takahari